Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore has won the Prix Galien France 2022 award in the ‘Medicine in Innovative Therapeutics’ category for its treatment KIMMTRAK (tebentafusp), the world’s first T cell receptor therapy for unresectable or metastatic uveal melanoma. Approved by the FDA and several health authorities in 2022, KIMMTRAK targets a rare and aggressive eye cancer that previously lacked specific treatments. This honor reflects both the therapy's impact on patients and the innovative technology developed by Immunocore, marking a successful year for the company.
Immunocore presented data for its bispecific T cell engager IMC-C103C targeting MAGE-A4 in ovarian cancer. The Phase 1 trial involved 33 heavily pre-treated patients. Results showed a manageable safety profile and some clinical activity, although the RECIST response rate was low among patients with low MAGE-A4 expression. Notably, reductions in ctDNA were observed even in patients with minimal MAGE-A4 expression. IMC-C103C is being co-developed with Genentech.
Immunocore Holdings plc (Nasdaq: IMCR) and Gadeta B.V. have entered a collaboration to develop the first gamma delta TCR ImmTAC® for treating solid tumors, including colorectal cancer. This partnership marries Gadeta's expertise in gamma delta TCRs with Immunocore's TCR bispecific engineering. Immunocore has an option for exclusive licensing of ImmTAC candidates resulting from this collaboration, and Gadeta is set to receive upfront fees and milestone payments. The new gamma delta TCRs exemplify a promising solution for patients without HLA restrictions.
Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 5th Annual Evercore ISI HealthCONx Conference scheduled for November 30, 2022, at 8:25 a.m. ET. The management will engage in a fireside chat, which will be available for live streaming and later as a replay on Immunocore's website.
Immunocore specializes in T cell receptor bispecific immunotherapies aimed at treating various diseases, including cancer and autoimmune disorders. Their lead product, KIMMTRAK, is approved for patients with metastatic uveal melanoma.
Immunocore has presented new data on KIMMTRAK (tebentafusp-tebn) for metastatic uveal melanoma at the SITC 2022 Annual Meeting. The analysis shows that gp100 protein expression remains unchanged relative to baseline during tumor progression. Notably, patients with progressive disease who maintain antigen processing machinery show longer overall survival. The study involved biopsies from 18 patients, highlighting a correlation between higher expression of antigen processing machinery components and better survival outcomes despite disease progression. KIMMTRAK aims to treat advanced melanoma effectively.
Immunocore Holdings Plc (Nasdaq: IMCR) will present at the Jefferies London Healthcare Conference on November 17, 2022, at 9:45 a.m. GMT. The presentation will be available via live webcast on Immunocore's website and a replay will follow temporarily. As a pioneering biotechnology company, Immunocore develops T cell receptor (TCR) bispecific immunotherapies targeting various diseases, including cancer. Their advanced treatment, KIMMTRAK, is approved for metastatic uveal melanoma in several key markets.
Immunocore reported Q3 2022 revenues of £36.3 million ($40.4 million) for KIMMTRAK, marking a 20% increase from Q2. The company's cash reserves stand at £347 million ($387 million). Clinical updates emphasize promising data from IMC-F106C targeting PRAME, highlighting its potential across tumor types. The company has expanded its prescribing accounts to 180 in the U.S. and received significant added benefit ratings in Germany. Additionally, Immunocore plans trials for tebentafusp in melanoma and other cancers, setting a positive outlook for continued growth.
Immunocore presented initial Phase 1 data for its off-the-shelf TCR therapy, IMC-F106C, targeting PRAME at the ESMO 2022 Congress. Results show that the therapy activates T cells and demonstrates durable RECIST responses and a reduction in circulating tumor DNA across various solid tumors. As of July 2022, 55 patients were treated, with manageable adverse events primarily involving Grade 1 cytokine release syndrome. Expansion arms are now enrolling for melanoma, ovarian, lung, and endometrial cancers.
Acacia Research Corporation (ACTG) reported a Q2 2022 revenue of $16.7 million, down from $17.4 million in Q2 2021. The company recorded $11.5 million in realized gains, including $5.2 million from its Life Science Portfolio. Acacia repurchased 6.1 million shares at an average price of $4.64 as part of a $40 million buyback program. Additionally, the company repaid $50 million in debt. However, there was a substantial GAAP net loss of $61.5 million compared to a net income of $19.7 million last year.
Immunocore reported Q2 2022 revenues of £27.7 million ($33.7 million) from KIMMTRAK, with U.S. sales at £18.1 million and European sales at £5.9 million. The company transitioned over 50 patients to commercial supply in Germany and finalized a randomized Phase 2/3 trial protocol for tebentafusp in advanced melanoma. Cash equivalents stood at £208 million ($253 million) as of June 30, 2022, following a £117 million PIPE financing in July. KIMMTRAK is now approved in over 30 countries, marking significant growth for the company.